Checkpoint Therapeutics Stock
Checkpoint Therapeutics Stock
With 8 Buy predictions and not the single Sell prediction the community is currently very high on Checkpoint Therapeutics.
Based on the current price of 0.5 € the target price of 30 € shows a potential of 5885.63% for Checkpoint Therapeutics which would more than double the current price.
Pros and Cons of Checkpoint Therapeutics in the next few years
Pros
?
G***** c******* t* c**********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Cons
?
C******** o* t** e**********
?
B****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Checkpoint Therapeutics vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Checkpoint Therapeutics | - | - | - | - | - | - | - |
Evolus Inc | -1.650% | 2.586% | 12.264% | 32.222% | 31.492% | 59.732% | - |
Ardelyx Inc. | -1.500% | -0.973% | 16.896% | 117.256% | 23.287% | 25.018% | - |
Salarius Pharmaceuticals Inc. | 0.960% | 1.449% | 0.000% | -63.478% | -24.324% | -98.369% | -99.992% |
Comments
Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $34.00 price target on the stock.
Show more
Ratings data for CKPT provided by MarketBeat
Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $34.00 price target on the stock.
Show more
Ratings data for CKPT provided by MarketBeat
Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) had its price target lowered by analysts at B. Riley from $8.00 to $4.00. They now have a "buy" rating on the stock.
Show more
Ratings data for CKPT provided by MarketBeat